Paratek Pharmaceuticals Announces Stockholder Approval Of Acquisition By Gurnet Point Capital And Novo Holdings A/S
Portfolio Pulse from Benzinga Newsdesk
Paratek Pharmaceuticals (NASDAQ:PRTK) has announced that its stockholders have approved the merger agreement proposal at a special meeting, in connection with the previously announced definitive agreement to be acquired by Gurnet Point Capital and Novo Holdings A/S. Final voting results will be disclosed on Form 8-K filed by Paratek with the U.S. Securities and Exchange Commission.
September 18, 2023 | 1:39 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Paratek Pharmaceuticals' stockholders have approved the company's acquisition by Gurnet Point Capital and Novo Holdings A/S. This could potentially lead to changes in the company's stock price.
The approval of the acquisition by the stockholders is a significant step towards the completion of the merger. This could potentially lead to changes in the company's stock price, depending on the terms of the acquisition and the market's reaction to it.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100